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Non-thyroidal illness syndrome (NTIS) is frequently detected in chronic, systemic diseases.
The objectives of the current study is to assess the alterations of thyroid hormones during
exacerbation period, recovery of exacerbation and stable phase of chronic obstructive
pulmonary disease (COPD) and correlates of these hormonal alterations.
A total of 83 stable COPD patients, 20 patients with acute exacerbation and 30 control
subjects were evaluated. TT3, fT3, TT3/TT4 levels of both stable and exacerbation COPD
groups were lower than control subjects. TSH was also decreased during exacerbation
period.
In follow-up of COPD exacerbation group, TSH, TT3, fT3 and TT3/TT4 were found to be
increased in measurements on the day of discharge from hospital and after 1 month,
compared to baseline values.
TT3 and TT3/TT4 were lower in severe COPD; whereas TSH, fT3, TT3 and TT3/TT4 were
lower in patients with severe hypoxemia. IL-6 and TNF-a were higher in both stable and
exacerbation phase COPD groups and IL-6 was correlated to TT3 in stable COPD.
As a result, there are significant alterations in thyroid hormones of stable COPD patients,
which are related to severity of disease and hypoxemia. The hormonal changes are more
significant during exacerbation and partially regress after 1 month when the disease is
stabilized. We conclude that COPD patients should not be evaluated for thyroid disease
during exacerbation of the disease, and thyroid function alterations during stable phase
of the disease should be considered cautiously, since thyroid function abnormalities inElsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is character-
ized by significant chronic inflammation not only in the
pulmonary compartment, but also in systemic circulation
and this disorder is associated with clinically significant
systemic alterations in biochemistry and organ function.1,2
Several factors such as hypoxemia, exacerbation, drugs,
malnutrition may lead to endocrinological changes in COPD.
Alterations in thyroid function tests are common in
critical illness, such as starvation, sepsis, surgery, myocar-
dial infarction, and also in chronic, systemic diseases
including chronic heart failure, chronic liver or hemotologic
diseases, cancer, diabetes, connective tissue diseases and
COPD.3 Frequently detected abnormalities of thyroid func-
tion in non-thyroidal illness (NTI) are decreased total
triiodothyronine (TT3) and free triiodothyronine (fT3),
normal or decreased total thyroxine (TT4) and free
thyroxine (fT4). Despite these changes, serum thyroid-
stimulating hormone (TSH) does not increase and can even
be decreased.4,5 Low serum TT3 is the most common
abnormality in NTI, observed in about 35–70% of hospitalized
patients.4,6 The terms ‘‘Non-thyroidal Illness Syndrome
(NTIS)’’ and ‘‘Euthyroid Sick Syndrome (ESS)’’ have been
used to describe these abnormalities.
Multiple, complex, usually reversible, and incompletely
understood mechanisms are involved in these abnormalities
such as disturbances in the hypothalamo–pituitary–thyroid
axis, thyroid hormone binding to serum proteins, tissue
uptake of thyroid hormones, and/or thyroid hormone
metabolism.4 Evaluation of these abnormalities is necessary
for diagnosis of thyroid disease since thyroid function
abnormalities in NTI may mimic or mask biochemical
abnormalities observed in true thyroid disease. Besides,
the severity and nature of these alterations may be a
prognostic indicator for the underlying disease. Low serum
T3 and/or T4 levels were reported to predict increased
mortality from diseases such as cirrhosis and advanced
congestive heart failure.7,8
Cytokines were demonstrated to be essential factors in
pathogenesis of both acute and chronic diseases. Although
the mechanisms underlying NTI are probably multifactorial,
these mediators may also be involved in the pathogenesis of
NTIS. As a matter of fact, similar thyroid hormone
alterations in different underlying diseases have been
associated with activation of cytokines.3 Proinflammatory
cytokines, especially IL-6, IL-1b, TNF-a and IFN-g are
important mediators of acute phase of the illness and have
inhibiting effects on peripheral thyroid hormone metabo-
lism.5,9,10
The objectives of the current study are to assess:(i) alterations of thyroid hormones during exacerbation
period, recovery of exacerbation and stable phase of
COPD;(ii) correlates of hormonal alterations and potential role of
endogenous cytokines TNF-a and IL-6 in hormonal
changes in COPD patients with different degrees of
functional impairment and hypoxemia.Material and methods
Patients
We enrolled 103 consecutive COPD patients who had
received a diagnosis of COPD and had received continuing
care at our chest clinic and 30 control subjects of the same
sex and age group. The diagnosis and severity of COPD had
been established by a respiratory physician on the basis of
international guidelines.11 A total of 83 patients had been
clinically stable for at least 3 months, and 20 had clinical
signs of COPD exacerbation.12 Clinical criteria used to define
an exacerbation were increased dyspnea, sputum produc-
tion, and sputum purulence. All patients were male and ex-
smokers. Stable COPD patients had been receiving inhaled
bronchodilator therapy in the form of long-acting b2 agonists
and /or anticholinergic agents. Severe/very severe COPD
patients were on inhaled corticosteroids (500–1000 mg
budesonide/day). Antibiotics and systemic steroids were
added to therapy only in exacerbation period for 10–14
days, after the blood samples were taken. After an
overnight fast, anthropometric measurements were made
and body mass index (BMI) was calculated. BMI between 19
and 25 was accepted as normal.13
Patient exclusion criteria included drug use which may
interfere with serum hormone levels such as amiodarone and
iodine-containing medication or contrast media, other
respiratory or endocrine system diseases, cardiovascular,
renal, hepatic, neuromuscular and collagen diseases,
malignancy, a known thyroid disease or previous thyroid
surgery. Control group consisted of subjects without COPD,
acute or chronic illness or drug intake that may alter
hormone levels.
The study was approved by the institutional committee on
human research and informed consent was obtained from all
subjects.Pulmonary function tests
Forced vital capacity (FVC) and forced expiratory volume in
1 s (FEV1) were measured with standard spirometric techni-
ques according to the ATS criteria (Minato AutoPal Spiro-
metry, Japan).14 The highest value from at least three
spirometric maneuvers was used. Patients with FEV1o50% of
predicted value were considered to have severe/very severe
and 50% pFEV1o80% as moderate COPD.11 Arterial blood
sample was obtained while the subjects were breathing
room air for at least 30min, and analyzed with a blood gas
analyzer immediately (OMNIC, Roche, Austria).
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NTIS in COPD 1441Thyroid function tests
After medical interview and thyroid examination, serum
levels of thyroid hormones (TSH, TT3, TT4, fT3, fT4) were
measured using electrochemiluminescence immunoassay
(Axsym, Abbott, Germany) and the ratio of TT3/TT4 was
calculated (normal limits for thyroid function tests:
TSH:0.49–4.67; TT3:0.45–1.37; TT4:4.5–12; fT3:1.45–3.48;
fT4:0.71–1.85). Thyroid hormones were measured once in
stable COPD patients and controls, and measured thrice in
COPD exacerbation group; on the first day of hospitalization
(before systemic steroids or antibiotics were given), on the
day of discharge from hospital (after 10–14 days of
treatment) and after 1 month.
Cytokine assays
Fasting blood samples (10ml) were collected by venipunc-
ture into plain tubes. Sera were obtained by centrifugation
at 1000g for 5min at room temperature. The samples were
stored at 70 1C until analysis.
Serum TNF-a concentration (pg/ml) was measured by a
solid phase sandwich ELISA using hTNF-a kit (BioSource
International Inc., California, USA). Serum IL-6 concentra-
tion (pg/ml) was also measured with enzyme-linked im-
munosorbent assay (ELISA) kits (Biosource International Inc.,
California, USA).
Statistical analysis
Data were presented as mean value7standard deviation of
the mean. Correlations between parameters were evaluatedTable 1 Characteristics and pulmonary function tests of entire
and control subjects.
COPD Stable
Subjects (n) 103 83
Age (yr) 66.5277.59 65.5477.66
Smoking (pack-year) 55.12725.07 53.58725.6
BMI 25.0174.96 25.2574.84
FVC 74.99714.52 75.78714.9
FEV1 44.39714.24 46.41714.4
FEV1/FVC% 46.33712.20 47.99712.2
pH 7.4070.04 7.4170.02
PaO2 70.35713.23 74.24710.3
PaCO2 43.3778.99 41.4676.00
*p value is obtained by comparison of stable and exacerbation phase
COPD, Chronic obstructive pulmonary disease; BMI: body mass index
expiratory volume in 1 s (%predicted); PaO2: Oxygen partial pressure
Table 2 Thyroidal status of stable and exacerbation phase CO
Thyroidal disease
Stable (n ¼ 83) n ¼ 8 (10%)
Exacerbation (n ¼ 20) n ¼ 4 (20%)
COPD, Chronic obstructive pulmonary disease; NTIS, Non-thyroidal ilusing ‘‘Pearson’ rank correlation analysis’’. Nonparametric
data of study groups were compared by ‘‘Mann–Whitney U
test’’. ‘‘One-way analyses of variance’’ was used to compare
differences in COPD subgroups. ‘‘Friedman’’ test was used to
compare baseline and subsequent control hormone levels of
COPD patients. Significance was determined at 5% level.
Results
Pulmonary function tests and arterial blood gases
Characteristics and pulmonary function tests of COPD
patients and control subjects admitted to the study are
shown in Table 1.
Thyroid function tests
Among 83 stable COPD patients, thyroid hormones of 25
were not within normal limits. Further diagnostic investiga-
tions revealed toxic multinodular goitre in 3, Hashimato’s
thyroiditis in 2, toxic adenoma in 2 and silent thyroiditis in 1
patient. These 8 patients were excluded from further
analyses and the remaining 17 patients (20%) were eval-
uated as NTIS (Table 2).
Thyroid hormones of 18 exacerbation phase COPD
patients were not within normal limits. Of these, 3 were
diagnosed as toxic multinodular goitre and 1 as Hashimato’s
thyroiditis. These 4 patients were excluded from further
analyses and the remaining 14 patients (70%) were eval-
uated as NTIS (Table 2). Thyroid hormone abnormalities
regarded as NTIS in both groups are given in Table 3.COPD patients, subgroups of stable and exacerbation phases,
Exacerbation Controls p*
20 30 —
68.6075.87 64.1077.68 0.064
3 61.50722.05 16.77715.78 0.134
24.0075.41 26.3273.07 0.154
7 71.69712.25 89.40710.35 0.264
3 36.0079.92 85.09710.24 0.003
4 39.4379.51 76.0376.21 0.006
7.3770.08 7.3870.04 0.048
9 54.21711.58 94.3274.62 0.000
51.30714.03 38.2373.46 0.002
COPD patients.
(kgm2); FVC: Forced vital capacity (%predicted); FEV1: Forced
(mmHg); PaCO2: Carbondioxide partial pressure (mmHg).
PD patients.
NTIS No thyroidal abnormalities
n ¼ 17 (20%) n ¼ 58 (70%)
n ¼ 14 (70%) n ¼ 2 (10%)
lness syndrome.
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Table 3 Thyroid hormone abnormalities evaluated as NTIS in stable and exacerbation phase COPD groups (patients with
thyroid disease are not included).
kTSH kTT3 kfT3 kfT4 kTSH/k fT3 kTT3/k fT3
Stable COPD (n ¼ 17) 13 2 1 1  
Exacerbation (n ¼ 14) 8  1  3 2
COPD, Chronic obstructive pulmonary disease; NTIS, Non-thyroidal illness syndrome.
Table 4 Serum thyroid hormones, IL-6 and TNF-a levels in COPD patients (entire group, stable and exacerbation subgroups)
and control subjects.
COPD Stable Exacerbation Controls p* p** p***
TSH 0.9670.41 1.0771.04 0.5170.48 0.8370.49 0.716 0.030 0.008
TT3 0.9470.41 0.9570.43 0.8770.32 1.1270.49 0.007 0.011 0.123
TT4 8.6672.33 8.5071.85 9.3373.72 8.2571.77 0.815 0.699 0.653
fT3 2.2770.68 2.2870.41 2.2171.32 3.0572.07 0.000 0.001 0.015
fT4 1.1170.40 1.0570.21 1.3470.78 1.1370.22 0.136 0.599 0.075
TT3/TT4 0.1270.54 0.1170.58 0.0970.26 0.1470.84 0.010 0.001 0.044
IL-6 70.577117.16 68.86750.42 71.407130.16 24.77747.23 0.012 0.019 0.802
TNF-a 13.14732.58 11.43711.91 14.87736.03 5.9975.29 0.033 0.034 0.449
*p value is obtained by comparison of stable COPD patients and control subjects.
**p value is obtained by comparison of COPD exacerbation group and control subjects.
***p value is obtained by comparison of stable and exacerbation groups of COPD patients.
COPD, Chronic obstructive pulmonary disease; TSH, Thyroid-stimulating hormone (mIU/ml); TT3, Total triiodothyronine (ng/ml); TT4,
Total thyroxine (mg/dl); fT3, Free triiodothyronine (pg/ml); fT4, Free thyroxine (ng/dl); IL-6, Interleukin-6 (pg/ml); TNF-a, Tumor
necrosis factor-alpha (pg/ml).
F. Karadag et al.1442Toxic multinodular goitre was detected in 1 subject in
control group. Thyroid hormones were within normal limits
in rest of them.
Thyroid hormone levels of the entire COPD group, stable
and exacerbation period COPD patients and control subjects
are shown in Table 4. Serum TT3, fT3 and TT3/TT4 of stable
COPD patients were lower than controls. In exacerbation
group, TSH was also lower besides TT3, fT3 and TT3/TT4.
When stable and exacerbation COPD groups were compared,
TT3, fT3 and TT3/TT4 were found lower in exacerbation
period. Taken together, TT3 and especially fT3 were lower in
COPD patients, and the alterations became more significant
during acute exacerbation of the disease.
In follow-up of COPD exacerbation group, TSH, TT3, fT3
levels and TT3/TT4 ratio were found to be increased in
measurements on the day of discharge from hospital and
after 1 month, compared to baseline values (Table 5).
Follow-up arterial blood gas analyses also revealed signifi-
cant changes in PaO2 and PaCO2 (Table 5). Hormonal
alterations improved as the arterial blood gas values
improved during recovery period of exacerbation.
Serum thyroid hormone levels of moderate (FEV1X50)
and severe (FEV1o50) COPD patients were given in Table 6.
TT3 and TT3/TT4 were lower in severe COPD compared to
moderate COPD, indicating that the degree of hormonal
alterations may be a marker of severity of the disease.
Thyroid hormones of COPD patients with moderate (804
PaO2X60mmHg) and severe hypoxemia (PaO2o60mmHg)
were shown in Table 7. TSH, TT3, fT3 levels were lower inpatients with severe hypoxemia. There was no difference
between thyroid hormones of hypercapnic (PaCO24
45mmHg) and normocapnic (PaCO2p45mmHg) patients
(p40.05 for all parameters).
BMI of COPD patients was lower than control subjects
(Table 1, p ¼ 0.042). Serum TSH was lower in COPD patients
with low (o19) BMI (p ¼ 0.008).
Cytokine assays
Serum IL-6 and TNF-a levels in COPD patients and control
subjects are given in Table 4. IL-6 and TNF-a concentrations
were higher in both stable and exacerbation phase COPD
groups than controls.
Correlations
In correlation tests of stable COPD patients, there was no
correlation between thyroid hormones and burden of
smoking or BMI. There was negative correlation between
age and TT3 (r ¼ 0.028, p ¼ 0.038), fT3 (r ¼ 0.278,
p ¼ 0,011) and TT3/TT4 (r ¼ 0.236, p ¼ 0.032). There was
positive correlation between pH and TSH (r ¼ 0.255
p ¼ 0.020) and PaO2 and TT3 (r ¼ 0.206, p ¼ 0.048), and
negative correlation between PaCO2 and TSH (r ¼ 0.229,
p ¼ 0.038). In COPD exacerbation group, there was positive
correlation between PaO2 and fT4 (r ¼ 0.450, p ¼ 0.046). In
stable COPD group, IL-6 was correlated to TT3 (r ¼ 0.712,
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Table 6 Thyroid hormones of moderate and severe
COPD patients.
Moderate COPD Severe COPD p
TSH 0.9470.94 0.9771.00 0.842
TT3 1.0870.66 0.8870.23 0.018
TT4 8.6871.96 8.6572.48 0.650
fT3 2.3470.39 2.2470.77 0.085
fT4 1.0870.24 1.1270.45 0.928
TT3/TT4 0.1370.08 0.1070.02 0.037
COPD, Chronic obstructive pulmonary disease; Moderate
COPD, Forced expiratory volume in 1 s (FEV1) X50%; Severe
COPD, FEV1o50%.
Table 7 Thyroid hormones of COPD patients with
moderate and severe hypoxemia.
Moderate hypoxemia Severe hypoxemia p
TSH 1.0270.90 0.8571.13 0.048
TT3 1.0070.47 0.8170.21 0.001
TT4 8.8572.38 8.2472.24 0.163
fT3 2.3870.75 2.0470.47 0.015
fT4 1.1270.45 1.0970.30 0.614
TT3/TT4 0.1170.06 0.1070.03 0.295
COPD, Chronic obstructive pulmonary disease; Moderate
hypoxemia, 804PaO2X60mmHg; Severe hypoxemia,
PaO2o60mmHg.
Table 5 Baseline, 1.control and 2.control thyroid hormone levels and blood gas analyses of COPD exacerbation patients.
Baseline 1. control 2. control p
TSH 0.5270.48 0.6670.63 1.2271.36 0.000
TT3 0.8870.33 0.7670.40 0.9670.29 0.041
TT4 9.3373.72 8.7073.46 8.0472.22 0.084
fT3 2.2171.32 2.1871.60 2.8070.68 0.001
fT4 1.3470.78 2.2273.79 1.1570.32 0.963
TT3/TT4 0.0970.26 0.2170.28 0.1970.21 0.043
PH 7.4070.04 7.3970.05 7.4170.02 0.188
PaO2 70.35713.23 72.3677.57 76.8177.15 0.036
PaCO2 43.3778.99 45.27710.31 39.6075.11 0.000
COPD, Chronic obstructive pulmonary disease; TSH, Thyroid-stimulating hormone (mIU/ml); TT3, Total triiodothyronine (ng/ml); TT4,
Total thyroxine (mg/dl); fT3, Free triiodothyronine (pg/ml); fT4, Free thyroxine (ng/dl); PaO2, Oxygen partial pressure (mmHg), PaCO2:
Carbondioxide partial pressure (mmHg).
NTIS in COPD 1443p ¼ 0.000) and TT3/TT4 (r ¼ 0.692, p ¼ 0,000); however
there was no correlation between other hormone para-
meters and TNF-a or IL-6 in both groups.Discussion
Non-thyroidal illness syndrome may be regarded as an acute
phase response of the organism that serves as one of themajor mechanisms of the body to restore homeostasis in
severe illness. Alterations in circulating thyroid hormone
concentrations have been reported in several acute and/or
chronic disease states.3 However, limited information exists
on thyroid function in COPD, since most studies have been
performed on small series of patients and mainly on those
with severe disease, usually without a control group.15–18
Extensive investigation of the mechanisms leading to
alterations in thyroid hormone metabolism seen in NTI has
failed to identify a single factor responsible for the observed
changes. It is likely that multiple factors determine these
characteristic changes in thyroid hormone metabolism. In
NTI, there is evidence for interference of normal hypotha-
lamic–pituitary–thyroid axis function, as well as altered
peripheral thyroid hormone transport and metabolism.4,6
Among previous studies, Semple et al. measured serum
TT3 and TT4 levels in 16 stable patients with severe COPD
and did not detect difference among hypercapnics, normo-
capnics and controls.17 The same investigators performed
thyroid stimulation tests in 8 hypoxic, stable patients with
severe COPD in a subsequent study and found that their
basal thyroid hormone levels were normal, but 2 patients
showed a delayed response to TRH. They concluded that
hypoxemia causes a minor change in the hypothalamic–pi-
tuitary–thyroid axis at the hypothalamic–pituitary (central)
level.15 However, the study group is too small to generalize
these findings.
Banks et al. measured thyroid hormones of 25 COPD
patients with various degrees of hypoxemia and hypercap-
nia.18 There was no relation between thyroid hormones and
pH, PaO2 or PaCO2 but there was an inverse correlation
between serum thyroxine and daily dose of oral predniso-
lone. They concluded that several endocrinological altera-
tions secondary to chronic pulmonary diseases might be
related to factors other than hypoxia and hypercapnia. In
the present study, there was no patient on regular systemic
steroids. Systemic steroids were added to therapy only in
exacerbation period, but baseline blood samples were taken
before the therapy.
Dimipoulou et al.3 demonstrated that serum thyroid
hormone levels were within normal limits in 46 COPD
patients with stable, mild-to-severe disease but they did
not have a control group to compare the results. While there
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F. Karadag et al.1444was no correlation between TT3, TT4, TT3/TT4 and study
parameters in patients with FEV1X50% predicted; there was
strong positive correlation between TT3/TT4 ratio and PaO2
in patients with FEV1o50%. They concluded that severity of
disease through hypoxemia is important in determining the
peripheral metabolism of thyroid hormones.
Okutan et al.19 evaluated the relation between thyroid
hormones and pulmonary function in moderate-to-severe
COPD. Thyroid hormone concentrations of COPD patients
were within normal limits, but fT3 was lower in COPD group
than controls. Besides, there was a negative correlation
between pulmonary function tests, PO2 and fT3 in COPD
patients.
In the present study, we evaluated 103 moderate-to-
severe COPD patients (mean FEV1 44%) and 30 controls with
normal pulmonary function. We found TT3 and fT3 levels
and TT3/TT4 ratio were lower in COPD group than controls
and the difference was more significant for fT3. Besides,
there was significant difference in TSH, TT3, fT3 levels and
TT3/TT4 ratio of stable and exacerbation groups. When we
evaluated the relation between pulmonary function tests
and thyroid hormones, we found out that serum TT3 and
TT3/TT4 ratio were lower in severe COPD compared to
moderate COPD.
TSH, TT3, fT3 levels were lower in patients with severe
hypoxemia (PaO2o60mmHg) when compared to patients
with milder hypoxia. We observed that fT4 decreased
parallel to PaO2 in exacerbation period. The decrease in
T3, fT3 and TT3/TT4 while T4 remains stable in patients
with severe airflow obstruction and patients in exacerbation
period with severe hypoxemia support the above-mentioned
studies indicating that hypoxemia and severity of COPD
affect peripheral metabolism of thyroid hormones. On the
other side, the degree of alteration in TT3 level may be a
useful marker of severity and prognosis of COPD, which
remains to be clarified by further studies.
We did not detect difference between thyroid hormones
of patients with and without hypercapnia. However, there
was inverse correlation between TSH and PaCO2 in stable
COPD group. That is why we consider hypercapnia may play
role in thyroid dysfunction besides hypoxemia.
We demonstrated that TSH, TT3, fT3 levels and TT3/TT4
ratio were lower than control subjects in 20 patients with
COPD exacerbation (mean FEV1 36% and mean PaO2
54mmHg), and increased in follow-up measurements on
the day of discharge from hospital and one month later. The
hormonal changes during follow-up after exacerbation
period seemed parallel to changes in PaO2 and PaCO2 and
hormonal alterations improved as the arterial blood gas
values improved during recovery period of exacerbation.
The increase in TSH levels when hypoxia was improved and
the disease become stable denotes delayed pituitary
response to TRH secondary to hypoxia.
On the contrary, Gow et al.16 did not find correlation
between arterial blood gases and thyroid hormones, and
therefore suggested that aging and illness per se might be
more important than hypoxemia in thyroid dysfunction.
Serum TT3, fT3 and TT3/TT4 decreased as age increased in
stable COPD in the present study, indicating decreased
metabolic clearance of T4 and decreased peripheral
conversion to T3. This inverse correlation suggested ageing
might also play role in thyroid dysfunction in addition tohypoxemia. As a matter of fact, Blum et al. evaluated
thyroid function in geriatric patients (mean age 8376) and
detected that TT3 was lower and fT4 was higher in aged
people.20
Decrease in BMI due to systemic inflammation and
oxidative stress was reported in COPD.21 BMI was lower in
COPD group than controls in our study. Serum TSH was found
to be lower in patients with low BMI compared to patients
with normal-to-high BMI, indicating that malnutrition may
also be related to hormonal changes in COPD.
The alterations in thyroid hormones in COPD might also be
related to factors other than hypoxia and hypercapnia. TNF-
a was demonstrated to be a mediator of several diseases
leading to hypothalamo–pituitary dysfunction. Investigation
of the effects of administering TNF-a and IL-1b to experi-
mental animals and humans confirmed a possible role for
them in the pathogenesis of NTIS, with each cytokine
inducing critical illness and changes of low serum T39,22–24
Both cytokines also induce IL-6 production.3 IL-6 is known to
exert regulatory effects upon many endocrine systems,
either independently, or acting with other cytokines.6,10,25
Stouthard et al. evaluated the effect of IV IL-6 administra-
tion on thyroid hormone metabolism in humans.10 IL-6
administration induced an acute decrease in T3 and TSH.
However, during prolonged sc administration of IL-6, these
effects seemed to be transient. After 1 week of daily
administration of IL-6, thyroid hormones returned to base-
line values. Therefore they concluded that acute elevations
of IL-6 may at least in part mediate the development of the
NTIS, whereas factors other than IL-6 contribute to the
persistence of changes in thyroid hormone concentrations
during chronic illness.
Davies et al. demonstrated a relation between elevated
serum IL-6 concentrations and alterations in circulating
thyroid hormones in NTI secondary to various medical
conditions.6 In the present study serum IL-6 and TNF-a
concentrations were higher in both COPD groups than
controls. In stable COPD group, IL-6 was correlated to TT3,
however there was no correlation between other hormone
parameters and TNF-a or IL-6 in both groups. Indeed, the
role of TNF-a in NTIS is controversial. Although TNF-a has
been shown to play role in NTIS in several experimental
studies, there is also opposite data. Boelen et al. showed
that immunoneutralization of IL-1, TNF-a or IFN-g did not
prevent NTIS in mice; however, immunoneutralization of IL-
6 transiently inhibited decrease of 50-deiodinase.26 Similarly,
Chopra et al. studied TNF-a concentration in NTI and found
in normal range.27 They did not detect correlation between
TNF-a and thyroid hormones and concluded that TNF-a is not
a universal or common factor in the pathogenesis of NTIS.
There is no adequate data on the prevalence of thyroid
dysfunction in COPD. Among 270 NTI patients (liver, renal,
cardiac disease and general medical or surgical conditions)
35% had a serum T3 below the normal range and 33% had
serum T4 below the normal range.6 The prevalence of NTIS
was reported as 18% in 199 patients with moderate-to-
severe congestive heart failure.28 We established NTIS in 17
of 83 (20%) stable COPD patients. Further studies are needed
to estimate the prevalence of thyroid dysfunction in COPD.
It is not clear if these patients with NTIS are metabolically
euthyroid or not. A normal serum TSH in most NTIS patients
with low T3 may indicate that they are metabolically
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NTIS in COPD 1445euthyroid. On the other hand, several studies demonstrate
abnormalities in the synthesis, secretion, glycosylation,
regulation and/or effectiveness of TSH in NTI.4 The transient
increase in serum TSH during recovery from NTI suggests
that TSH is suppressed in an illness.29,30 Overall, although
patients with NTI may be euthyroid because of short
duration of NTIS, those with a prolonged NTI may be
biochemically hypothyroid and may benefit from thyroid
hormone replacement therapy.4 However, studies evaluating
T3 replacement treatment in NTIS yielded either no benefit,
or appreciable improvement.31–33 Further studies are
needed to clarify the appropriate patient population,
dose–response and adverse effects of treatment of NTIS
with low T3.
The results of the present study not only confirm and
enhance the previous findings on thyroid hormone altera-
tions in stable COPD patients, but also add information on
thyroid function changes during acute exacerbation period
and recovery phase. In summary, there are alterations in
thyroid hormones in COPD which is a systemic disease. The
hormonal alterations are especially related to severity of
the disease and hypoxemia. There are differences in
hormone levels during stable and exacerbation phases of
COPD; the hormonal changes are more significant during
exacerbation and partially regress after 1 month when the
disease is stabilized. The pattern of hormonal changes
suggests that hypoxemia acts not only at the central level of
HPTaxis, but also interferes with the peripheral metabolism
and turnover of thyroid hormones.
As a conclusion, as there are significant alterations in
thyroid hormones of COPD patients, we suggest that they
should not be evaluated for thyroid disease during exacer-
bation of the disease, and thyroid function alterations
during stable phase of the disease should be considered
cautiously, since thyroid function abnormalities in non-
thyroid illness may mimic or mask biochemical abnormalities
observed in true thyroid disease. Whether NTIS in COPD is a
useful compensatory mechanism to counteract excessive
catabolism and protein breakdown; or is an unfavourable
adaptation and these patients are indeed biochemically
hypothyroid, and will benefit from thyroid hormone replace-
ment therapy remains to be clarified by further studies.
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